Designing ATHN 7: Safety, effectiveness and practice of treatment of people with haemophilia in the United States through a natural history cohort study

1 Iorio A, Stonebraker JS, Chambost H, et al.; Data and Demographics Committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med 2019; 171(8): 540–546. doi: 10.7326/M19-1208. IorioA StonebrakerJS ChambostH Data and Demographics Committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries Ann Intern Med 2019 171 8 540 546 10.7326/M19-1208 31499529 Open DOISearch in Google Scholar

2 Marchesini E, Morfini M, Valentino L. Recent advances in the treatment of haemophilia A: a review. Biologics 2021; 15: 221–235. doi: 10.2147/BTT.S252580. MarchesiniE MorfiniM ValentinoL Recent advances in the treatment of haemophilia A: a review Biologics 2021 15 221 235 10.2147/BTT.S252580 821453934163136 Open DOISearch in Google Scholar

3 Weyand AC, James PD. Sexism in the management of bleeding disorders. Res Pract Thromb Haemost 2020; 5(1): 51–54. doi: 10.1002/rth2.12468. WeyandAC JamesPD Sexism in the management of bleeding disorders Res Pract Thromb Haemost 2020 5 1 51 54 10.1002/rth2.12468 784507033537529 Open DOISearch in Google Scholar

4 van Galen KPM, d'Oiron R, James P, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost 2021; 19(8): 1883–1887. doi: 10.1111/jth.15397. van GalenKPM d'OironR JamesP A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH J Thromb Haemost 2021 19 8 1883 1887 10.1111/jth.15397 836171334327828 Open DOISearch in Google Scholar

5 Berntorp E, Fischer K, Hart DP, et al. Haemophilia. Nat Rev Dis Primers 2021; 7(1): 45. doi: 10.1038/s41572-021-00278-x. BerntorpE FischerK HartDP Haemophilia Nat Rev Dis Primers 2021 7 1 45 10.1038/s41572-021-00278-x 34168126 Open DOISearch in Google Scholar

6 Chen S-L. Economic costs of haemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care 2016; 22(5 Suppl): s126–33. ChenS-L Economic costs of haemophilia and the impact of prophylactic treatment on patient management Am J Manag Care 2016 22 5 Suppl s126 33 Search in Google Scholar

7 Gualtierotti R, Tafuri F, Arcudi S, et al. Current and emerging approaches for pain management in hemophilic arthropathy. Pain Ther 2022; 11(1): 1–15. doi: 10.1007/s40122-021-00345-x. GualtierottiR TafuriF ArcudiS Current and emerging approaches for pain management in hemophilic arthropathy Pain Ther 2022 11 1 1 15 10.1007/s40122-021-00345-x 886124335020184 Open DOISearch in Google Scholar

8 Barry V, Buckner TW, Lynch ME, et al. An evaluation of PROMIS health domains in adults with haemophilia: A cross-sectional study. Haemophilia 2021; 27(3): 375–382. doi: 10.1111/hae.14321. BarryV BucknerTW LynchME An evaluation of PROMIS health domains in adults with haemophilia: A cross-sectional study Haemophilia 2021 27 3 375 382 10.1111/hae.14321 33866654 Open DOISearch in Google Scholar

9 DeKoven M, Karkare S, Kelley LA, et al. Understanding the experience of caring for children with haemophilia: cross-sectional study of caregivers in the United States. Haemophilia 2014; 20(4): 541–9. doi: 10.1111/hae.12379. DeKovenM KarkareS KelleyLA Understanding the experience of caring for children with haemophilia: cross-sectional study of caregivers in the United States Haemophilia 2014 20 4 541 9 10.1111/hae.12379 24472032 Open DOISearch in Google Scholar

10 Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(9): 809–818. doi: 10.1056/NEJMoa1703068. OldenburgJ MahlanguJN KimB Emicizumab prophylaxis in hemophilia A with inhibitors N Engl J Med 2017 377 9 809 818 10.1056/NEJMoa1703068 28691557 Open DOISearch in Google Scholar

11 Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379(9): 811–822. doi: 10.1056/NEJMoa1803550. MahlanguJ OldenburgJ Paz-PrielI Emicizumab prophylaxis in patients who have hemophilia A without inhibitors N Engl J Med 2018 379 9 811 822 10.1056/NEJMoa1803550 30157389 Open DOISearch in Google Scholar

12 Ellsworth P, Ma A. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? Hematology Am Soc Hematol Educ Program 2021; 2021(1): 219–225. doi: 10.1182/hematology.2021000253. EllsworthP MaA Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? Hematology Am Soc Hematol Educ Program 2021 2021 1 219 225 10.1182/hematology.2021000253 879112334889356 Open DOISearch in Google Scholar

13 McGill JR, Simhadri VL, Sauna ZE. HLA Variants and inhibitor development in hemophilia A: a retrospective case-controlled study using the ATHN dataset. Front Med (Lausanne) 2021; 8: 663396. doi: 10.3389/fmed.2021.663396. McGillJR SimhadriVL SaunaZE HLA Variants and inhibitor development in hemophilia A: a retrospective case-controlled study using the ATHN dataset Front Med (Lausanne) 2021 8 663396 10.3389/fmed.2021.663396 813940534026790 Open DOISearch in Google Scholar

14 Male C, Andersson NG, Rafowicz A, et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica 2021; 106(1): 123–129. doi: 10.3324/haematol.2019.239160. MaleC AnderssonNG RafowiczA Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study Haematologica 2021 106 1 123 129 10.3324/haematol.2019.239160 777624631919092 Open DOISearch in Google Scholar

15 Garagiola I, Palla R, Peyvandi F. Risk factors for inhibitor development in severe hemophilia a. Thromb Res 2018; 168: 20–27. doi: 10.1016/j.thromres.2018.05.027. GaragiolaI PallaR PeyvandiF Risk factors for inhibitor development in severe hemophilia a Thromb Res 2018 168 20 27 10.1016/j.thromres.2018.05.027 29879570 Open DOISearch in Google Scholar

16 Valentino LA, Kempton CL, Kruse-Jarres R, et al.; International Immune Tolerance Induction Study Investigators. US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors. Haemophilia 2015; 21(5): 559–67. doi: 10.1111/hae.12730. ValentinoLA KemptonCL Kruse-JarresR International Immune Tolerance Induction Study Investigators. US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors Haemophilia 2015 21 5 559 67 10.1111/hae.12730 26032231 Open DOISearch in Google Scholar

17 Davis JA, Klamroth R, Benchikh El Fegoun S, Habis R, de Moerloose P. A survey among patients with haemophilia and inhibitors or their caregivers, seeking treatment in nonhaemophilia treatment centres. Haemophilia 2020; 26(4): e205–e208. doi: 10.1111/hae.13983. DavisJA KlamrothR Benchikh El FegounS HabisR de MoerlooseP A survey among patients with haemophilia and inhibitors or their caregivers, seeking treatment in nonhaemophilia treatment centres Haemophilia 2020 26 4 e205 e208 10.1111/hae.13983 32267042 Open DOISearch in Google Scholar

18 Valentino LA, Baker JR, Butler R, et al. Integrated hemophilia patient care via a national network of care centers in the United States: a model for rare coagulation disorders. J Blood Med 2021; 12: 897–911. doi: 10.2147/JBM.S325031. ValentinoLA BakerJR ButlerR Integrated hemophilia patient care via a national network of care centers in the United States: a model for rare coagulation disorders J Blood Med 2021 12 897 911 10.2147/JBM.S325031 854426534707421 Open DOISearch in Google Scholar

19 World Medical Association. WMA Declaration of Helsinki – Ethical principles for medical research involving human subjects. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-formedical-research-involving-human-subjects/ (accessed 21 November 2022). World Medical Association WMA Declaration of Helsinki – Ethical principles for medical research involving human subjects Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-formedical-research-involving-human-subjects/ (accessed 21 November 2022). Search in Google Scholar

20 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12(11): 1935–9. doi: 10.1111/jth.12672. BlanchetteVS KeyNS LjungLR Manco-JohnsonMJ van den BergHM SrivastavaA Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH J Thromb Haemost 2014 12 11 1935 9 10.1111/jth.12672 25059285 Open DOISearch in Google Scholar

21 Makris M, Calizzani G, Fischer K, et al. EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res 2011; 127 Suppl 2: S22–5. doi: 10.1016/S0049-3848(10)70150-X. MakrisM CalizzaniG FischerK EUHASS: The European Haemophilia Safety Surveillance system Thromb Res 2011 127 Suppl 2 S22 5 10.1016/S0049-3848(10)70150-X 21193110 Open DOISearch in Google Scholar

22 Boylan B, Miller CH. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. Haemophilia 2018; 24(3): 487–491. doi: 10.1111/hae.13435. BoylanB MillerCH Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels Haemophilia 2018 24 3 487 491 10.1111/hae.13435 607256529461004 Open DOISearch in Google Scholar